The startup's software uses AI agents to monitor studies. OpenAI plans to connect research findings with the work needed to advance potential medicines.
Ascendis Pharma reported long-term Phase 3 data showing Yorvipath sustained biochemical control and reduced supplement reliance in hypoparathyroidism patients over 3.5 years.
Incyte announced Phase 3 results showing its tafasitamab plus lenalidomide regimen significantly improved progression-free survival in high-risk lymphoma patients.
